Drug profile · INN
irbesartan
ABISART 150
irbesartan (ABISART 150) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — irbesartan
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- ORAL
- Patents
- 2
- Programs
- 5
- Data quality
- 0.89
Quick answer
irbesartan (ABISART 150) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is irbesartan?
irbesartan (ABISART 150) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for irbesartan?
ABISART 150 is a marketed brand name for irbesartan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of irbesartan?
irbesartan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.